AzTrials
AzTrials

HealthyNCT03950999

Experimental Pain Reporting Accuracy and Placebo Response

A study of Healthy and Placebo Effect, run by University of Haifa at 1 site in Israel.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Good clinical care relies on precise evaluation of patients' conditions. Chronic pain and other neurological and psychiatric diagnoses pose challenges because their assessment depends on subjective patient-reported outcome measures (PROs). Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Healthy, Placebo Effect, Pain
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
100 participants
Where
1 siteIsrael
Study dates
13 Aug 2017to Jun 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • absence of acute or chronic pain disorders;
  • no reports of psychiatric, cognitive and /or neurological disorders;
  • no drugs including, analgesics or anti-anxiety medications on regular use (except for oral contraceptives).

Who cannot join

  • pregnant or breast-feeding;
  • unable to give informed consent, communicate and understand the purpose and the instructions of the study.

Trial locations and contacts

1 site in 1 country.

Israel1 site, 1 recruiting
  • University of Haifa, The Clinical Pain Innovation Lab

    Haifa, 3498838

    Roi Treister, PhD, 972-(0)4-6146214, treister.roi@gmail.com

    Recruiting

Other trials in Israel

About this study

Official title: Pain and Placebo - a Study to Examine Relations Between Pain Reporting Accuracy and the Response to Experimental Placebo Model

Good clinical care relies on precise evaluation of patients' conditions. Chronic pain and other neurological and psychiatric diagnoses pose challenges because their assessment depends on subjective patient-reported outcome measures (PROs). The investigators have recently developed the Focused Analgesia Selection Task (FAST), a method that allows assessing pain reporting accuracy. Preliminary results suggest that those who more accurately report their pain show diminished placebo response. The underlying mechanisms for this observation cannot be explained by current theories. Therefore, the investigators have conducted a pilot study to further characterize this relation in healthy population.

Read the detailed description

Instruments and procedures:

Instruments All stimuli were applied by a contact-heat Thermal Sen-sory Analyzer 2001 system (Medoc, Ramat-Yishai, Israel) with a 30 x 30mm Peltier surface stimulator, which was attached by Velcro straps to the volar surface of the forearm of the subjects' hand.

Familiarization session At the beginning of the experimental session, all subjects underwent short training in order to familiarize them with the device and with the sensations evoked by the painful stimulation, and to train them to report their perceived pain intensity using the numerical pain scale. The training included exposure to three short contact-heat stimuli (44, 46.5, and 48°C), each lasting for 7 seconds from the time that the stimulation intensity reached the destination temperature. The thermode was moved following each stimulus to a completely distinct, adjacent area of skin. Subjects were asked to report the numerical pain score (NPS), on a scale ranging from 0, denoting no pain, to 100, denoting the worst pain imaginable, induced by each stimulus.

Pain reporting accuracy assessment:

The subject's pain reporting accuracy skills was assessed by the FAST, which is based on recording a subject's pain reports in response to repeated administration of thermal noxious stimuli of various intensities. During the FAST procedure the thermode was attached to the ventral surface of the subject's non-dominant arm and the temperature was raised from a baseline of 32°C, peaked for 3 seconds at 1 of 7 designated temperatures (44°C, 45°C, 46°C, 47°C, 48°C, 49°C, and 50°C), and then decreased down to the baseline. Stimulus rate of rise and fall was kept constant at 8°C/seconds. Subjects were asked to rate the peak pain intensity of each stimulus verbally using the NPS. Each temperature was presented 7 times in a random block-ordered design (49 stimuli in total). Inter-stimulus intervals of 20 seconds allowed the subject sufficient time to rate the pain they perceived during each stimulus. The location of the thermode was adjusted every 10 stimuli to minimize sensitization and/or habituation effects. The duration of the FAST procedure is ~25 minutes.

Placebo assessment:

The placebo effect was assessed using tonic heat delivered at fixed temperature of either 44, 46.5, and 48°C. As was shown by previous studies, these temperatures evokes mild, moderate and severe pain sensations. During the stimuli, the thermode was attached to the volar surface of the forearm of the subjects' dominant hand. Baseline temperature was 32.0 °C, with an increasing temperature rate of 2°C/s and a return-to-baseline temperature rate of 8°C/s. Pain intensity ratings of heat stimuli were assessed verbally using NPS, at 2, 10 and 20 sec after the initiation of the stimulus.

Placebo procedure:

Each subject received clinical trial-type instructions before receiving the placebo so that the condition of the study would be similar to those encountered in typical drug trials. Subjects consented to participate in a study examining the analgesic effects of a well-known established pain relief medication. The subjects were told that they were about to receive a pain relief medication, which is commonly used in clinical practice. Possible adverse effects of the substance in question were then described, but it was indicated that the investigators did not typically observe significant adverse effects. Actual pharmacological agents were not administered.

Study design:

All experiments were conducted in the same setting, by the same investigator. The experiment was performed in a quiet room with an ambient temperature of 23°C. After the familiarization stage, the experiment begun with delivery of the FAST. After a 10 min break, subjects received the three tonic heat stimuli, each lasting 20 sec long, in a pseudo-random order with 60 sec break between each stimulus. Thereafter each subject was given a placebo pill. In order to evaluate placebo effect, the tonic heat stimuli were administered 20 minutes after placebo intake maintaining the same stimuli order.

The net placebo effect (Δ) was calculated as the difference between the mean NPS of the mild, moderate, and severe pain stimuli administrated before the placebo (Pre-placebo) minus the same after placebo (Post-placebo). The placebo effect in percent was calculated as the ratio of Post-placebo to Pre-placebo double 100. Positive values indicate efficient placebo effect.

The total duration of the experimental session was approximately 1 hours and 30 minutes.

Being tested
Placebo
Keywords
Focus analgesia selection test (FAST), Placebo effect, Experimental pain variability
Medical subject headings
Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PlaceboOther

    Sugar pill

Study groups in NCT03950999
Study groupRoleWhat they receive
Study armExperimentalEach subject underwent baseline assessment of pain reporting accuracy (FAST). Thereafter, the placebo response was assessed using tonic heat stimuli delivered at fixed temperature of 44, 46.5, and 48°C which evoke mild, moderate and severe pain sensations (in accordance). The stimuli were given in a pseudo-random order twice, once before receiving the placebo pill (a sugar pill) and once after, maintaining the same order as before.
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain reporting accuracy

    Subjects will be asked to report their pain on numerical pain scale (NPS) ranging from 0, denoting "no pain", to 10, denoting "the worst pain imaginable".

    Measured: Fast procedure itself (49 heat stimuli, from 7 designated heat temperatures, given in a random block-order design) lasting approximately 20 minutes.

  2. Change in experimental pain perception due to placebo pill intake

    Subjects will be asked to report their pain on numerical pain scale (NPS) ranging from 0, denoting "no pain", to 10, denoting "the worst pain imaginable". The placebo effect (Δ) will be calculated as the difference between the mean NPS.

    Measured: Tonic stimuli before the placebo (Pre-placebo) until receiving the same stimuli 20 minutes after taking the placebo pill (Post-placebo).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 May 2019
  2. Study start13 Aug 2017
  3. Primary completionJun 2019 (estimated)
  4. Study completionJun 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03950999
Sponsor's protocol ID
273/17
Status last verified
May 2019
First submitted
7 May 2019
Last updated
15 May 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study of Healthy and Placebo Effect, run by University of Haifa at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 May 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Roi Treister, PhD (972-(0)4-6146214, treister.roi@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain reporting accuracy (time frame: Fast procedure itself (49 heat stimuli, from 7 designated heat temperatures, given in a random block-order design) lasting approximately 20 minutes.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT03950999 | AzTrials